FDA recall record

Biomerieux ETEST IMIPENEM RELEBACTAM. in vitro diagnostic recall — FDA Z-2226-2021

Major errors (Resistant result instead of Susceptible result) were observed with Pseudomonas aeruginosa strains.

Class IIclassification
Z-2226-2021official record ID
Aug 18, 2021report date

Recall record at a glance

Official recordZ-2226-2021
CategoryMedical Device Recalls
ClassificationClass II
FDA record statusTerminated
Recalling firmBiomerieux Inc.
Report dateAug 18, 2021
Recall initiation dateJun 24, 2021
Quantity1,431
LocationHazelwood, MO, United States

Official product description

ETEST IMIPENEM RELEBACTAM. in vitro diagnostic

Why the product was recalled

Major errors (Resistant result instead of Susceptible result) were observed with Pseudomonas aeruginosa strains.

Distribution information

Worldwide distribution - US Nationwide distribution including in the states of AR, AZ, CA, CO, DE, FL, GA, IL, IN, KS, KY, MA, MD, ME, MI, MN, MO, NC, NE, NH, NJ, NV, NY, OH, OK, PA, SC, TN, TX, UT, VA, WA, WI, WV and Hawaii. The countries of Austria, Belgium, Croatia, Czech Republic, France, Germany, Greece, Italy, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland and United Kingdom.

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.

Medical DeviceMay 1, 2024

Biomerieux VITEK 2 - AST Test kits recall — FDA Z-1464-2024

Ceftriaxone (cro02n) concentration errors associated with specific recently manufactured test kits which would have the potential for for false susceptible results. The risk is present for…

Class IFDA: OngoingBiomerieux Inc.